Modafinil

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Modafinil

Examples of brand names: Vigil [DE]

ATC code: N06BA07

Main use (for orientation): Narcolepsy

Documented research summary

Placebo-controlled crossover in 12 people with 400 mg modafinil and 15 mg oral THC: the authors found no additional relevant safety concern in this small acute experiment; not proof of general combination safety or reliable long-term/pharmacokinetic assurance.

Uncertainties and limitations

PMC3645879 full-text download failed; abstract-based. Reservation retained despite the positively worded article title. Documented individual title/abstract assessment with selected relevant full texts; not an exhaustive worldwide systematic review or independent human specialist approval. Missing data do not establish safety. All 28 cannabinoids are within the search scope, not 28 clinically investigated pairs per drug.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

THC – clinically investigated

Finding ID: B0498

Type of result: Context-specific finding

Observation: No clear additional safety signal from the combination reported in the small acute experiment.

Mechanism: Assessment of acute modafinil and THC combination.

Study type: Double-blind four-condition human crossover

Context studied: Twelve people, modafinil 400 mg and THC 15 mg; original abstract.

Clinical interpretation: Human endpoint directly studied under narrowly defined study conditions; long-term safety and generalisability not established.

Limitations and uncertainties: Not an equivalence, long-term or high-risk-patient study; do not interpret an absent signal as general safety.

Original sources for this finding: The safety of modafinil in combination with oral ∆9-tetrahydrocannabinol in humans. [VF_P_21176784]

References and access status

[VF_L_D0432] PROVIGIL (MODAFINIL) TABLET [GOLDEN STATE MEDICAL SUPPLY, INC.]

Original source / bibliographic reference

Authors: Marketing authorisation holder; official product information via DailyMed

Year: 2025

Source type: Official medicine information; relevant identity, PK, PD and DDI sections read individually

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VF_P_21176784] The safety of modafinil in combination with oral ∆9-tetrahydrocannabinol in humans.

Original source / bibliographic reference

Authors: Sugarman DE, Poling J, Sofuoglu M.

Year: 2011

Source type: Scientific publication; precise study type and suitability described in the finding or individual review

DOI: 10.1016/j.pbb.2010.12.013

PMID: 21176784

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility